End-of-day quote
Taipei Exchange
06:00:00 2024-06-03 pm EDT
|
5-day change
|
1st Jan Change
|
23.4
TWD
|
-3.11%
|
|
-3.70%
|
-7.87%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,146
|
884.3
|
1,467
|
2,396
|
1,479
|
1,355
|
Enterprise Value (EV)
1 |
833.6
|
646.3
|
1,199
|
2,176
|
1,378
|
1,230
|
P/E ratio
|
-8.23
x
|
-9.65
x
|
-20.9
x
|
-25.6
x
|
-12.5
x
|
-13.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-6.86
x
|
-6.85
x
|
-17
x
|
-24.4
x
|
-12
x
|
-13.8
x
|
EV / FCF
|
-11.4
x
|
-14.2
x
|
-31.5
x
|
-39.1
x
|
-18.1
x
|
-28
x
|
FCF Yield
|
-8.77%
|
-7.02%
|
-3.18%
|
-2.56%
|
-5.52%
|
-3.57%
|
Price to Book
|
3.3
x
|
3.27
x
|
4.92
x
|
9.63
x
|
11.2
x
|
9.69
x
|
Nbr of stocks (in thousands)
|
44,059
|
44,216
|
44,387
|
49,142
|
49,292
|
53,349
|
Reference price
2 |
26.00
|
20.00
|
33.05
|
48.75
|
30.00
|
25.40
|
Announcement Date
|
4/17/19
|
4/8/20
|
4/21/21
|
4/15/22
|
4/25/23
|
4/11/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-121.5
|
-94.29
|
-70.41
|
-89.24
|
-115.2
|
-89.32
|
EBIT
1 |
-125.7
|
-98.84
|
-75.79
|
-94.43
|
-119.8
|
-93.34
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-111.3
|
-91.62
|
-70.16
|
-92.69
|
-118.4
|
-92.11
|
Net income
1 |
-111.3
|
-91.62
|
-70.16
|
-92.69
|
-118.4
|
-92.11
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-3.157
|
-2.073
|
-1.583
|
-1.902
|
-2.399
|
-1.828
|
Free Cash Flow
1 |
-73.14
|
-45.36
|
-38.09
|
-55.71
|
-76.12
|
-43.87
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/17/19
|
4/8/20
|
4/21/21
|
4/15/22
|
4/25/23
|
4/11/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
312
|
238
|
268
|
220
|
101
|
125
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-73.1
|
-45.4
|
-38.1
|
-55.7
|
-76.1
|
-43.9
|
ROE (net income / shareholders' equity)
|
-39.7%
|
-29.6%
|
-24.6%
|
-33.8%
|
-62.1%
|
-67.8%
|
ROA (Net income/ Total Assets)
|
-26.9%
|
-19.4%
|
-15.9%
|
-20.5%
|
-37.3%
|
-40.4%
|
Assets
1 |
414.6
|
473.1
|
441
|
452.8
|
317.2
|
228
|
Book Value Per Share
2 |
7.870
|
6.110
|
6.720
|
5.060
|
2.670
|
2.620
|
Cash Flow per Share
2 |
0.3100
|
0.2800
|
2.740
|
0.2900
|
0.3600
|
1.220
|
Capex
1 |
0.34
|
0.04
|
0.63
|
0.52
|
0.21
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/17/19
|
4/8/20
|
4/21/21
|
4/15/22
|
4/25/23
|
4/11/24
|
|
1st Jan change
|
Capi.
|
---|
| -7.87% | 38.6M | | +46.19% | 55.7B | | -6.14% | 39.57B | | +39.19% | 39.91B | | -6.65% | 28.16B | | +12.33% | 26.3B | | -21.78% | 18.94B | | -0.35% | 12.12B | | +24.18% | 12.12B | | +28.38% | 12.17B |
Other Biotechnology & Medical Research
|